Tag: Phase I
-
Engineered Salmonella Therapy Delivers Immune Payloads to Fight Cancer
New Bacterial Immunotherapy Targets Solid Tumors Researchers have unveiled ACTM-838, a novel, systemically delivered bacterial immunotherapy designed to enrich solid tumors with immune-stimulating payloads. Published in Volume 16 of Oncotarget on October 6, 2025, the study demonstrates how a specially engineered Salmonella Typhimurium strain can safely localize to tumors and deliver potent immune activators directly…